Emerging therapies in gastrointestinal cancers.

Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Transl Oncol (2009) 1.68

Age-related increase in colorectal cancer stem cells in macroscopically normal mucosa of patients with adenomas: a risk factor for colon cancer. Biochem Biophys Res Commun (2008) 1.31

Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol (2008) 1.07

EGFR regulation of colon cancer stem-like cells during aging and in response to the colonic carcinogen dimethylhydrazine. Am J Physiol Gastrointest Liver Physiol (2012) 1.00

ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. Mol Cancer Ther (2010) 0.93

Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice. Gastroenterology (2009) 0.90

JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression? World J Gastroenterol (2007) 0.90

Regulation of colon cancer recurrence and development of therapeutic strategies. World J Gastrointest Pathophysiol (2012) 0.81

EGFR(s) in aging and carcinogenesis of the gastrointestinal tract. Curr Protein Pept Sci (2010) 0.81

EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new? Curr Drug Targets (2010) 0.76

Cetuximab alleviates neuropathic pain despite tumour progression. BMJ Case Rep (2012) 0.75

Role of cancer stem cells in age-related rise in colorectal cancer. World J Gastrointest Pathophysiol (2015) 0.75

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88

Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05

The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 9.51

Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03

Global cancer statistics. CA Cancer J Clin (1999) 8.82

EGFR and cancer prognosis. Eur J Cancer (2001) 7.52

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature (2003) 6.78

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science (1995) 6.58

Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res (2003) 6.43

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A (2003) 6.37

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer (2001) 5.96

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J (1997) 5.70

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol (2003) 5.22

Strain-dependent epithelial defects in mice lacking the EGF receptor. Science (1995) 5.22

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res (2002) 4.98

The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta (1994) 4.92

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell (2002) 4.92

Epidermal growth factor. J Biol Chem (1990) 4.79

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther (2001) 4.37

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03

EGF receptor. Int J Biochem Cell Biol (1999) 3.91

Induction of apoptosis by cancer chemotherapy. Exp Cell Res (2000) 3.51

Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A (2000) 3.44

Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J (1994) 3.42

Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol (1994) 3.42

Specificity within the EGF family/ErbB receptor family signaling network. Bioessays (1998) 3.37

Membrane-anchored growth factors. Annu Rev Biochem (1993) 3.26

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett (1997) 3.23

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res (1997) 3.18

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res (2001) 3.18

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res (2001) 3.02

The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther (1999) 2.89

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol (1999) 2.66

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res (1990) 2.56

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science (1988) 2.35

Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer (2003) 2.29

Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst (2003) 2.23

Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol (1994) 2.20

Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J (2002) 2.17

Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A (1998) 2.15

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol (2002) 2.14

Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol (1995) 2.13

Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist (2002) 2.05

The EGF receptor: a nexus for trafficking and signaling. Bioessays (2000) 2.02

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell (1998) 2.00

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer (2002) 1.97

Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res (1997) 1.91

Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci U S A (1997) 1.89

The maternal ventralizing locus torpedo is allelic to faint little ball, an embryonic lethal, and encodes the Drosophila EGF receptor homolog. Cell (1989) 1.82

EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science (1990) 1.76

The Drosophila EGF receptor homolog (DER) gene is allelic to faint little ball, a locus essential for embryonic development. Cell (1989) 1.73

Multiple functions of let-23, a Caenorhabditis elegans receptor tyrosine kinase gene required for vulval induction. Genetics (1991) 1.73

Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat (1995) 1.63

Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol (1995) 1.63

Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem (1999) 1.59

Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J (1998) 1.57

Memo mediates ErbB2-driven cell motility. Nat Cell Biol (2004) 1.47

The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer (2001) 1.46

Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther (2005) 1.44

Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin (2003) 1.44

Role of HER receptors family in development and differentiation. J Cell Physiol (2004) 1.44

Epidermal growth factor receptor signaling. Curr Biol (2001) 1.43

Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol (1998) 1.41

Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim Biophys Acta (2002) 1.37

Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene (1999) 1.34

Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J (1991) 1.33

Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol (2003) 1.33

Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev (2001) 1.33

c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene (1998) 1.30

Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins. J Biol Chem (2001) 1.29

Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am (1997) 1.28

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol (1998) 1.27

Implication of a multisubunit Ets-related transcription factor in synaptic expression of the nicotinic acetylcholine receptor. EMBO J (1998) 1.26

c-erbB-4 protein expression in human breast cancer. Br J Cancer (2000) 1.25

Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. J Biol Chem (2000) 1.21

Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene (1999) 1.21

Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther (1999) 1.17

Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene (1995) 1.16

Epidermal growth factor receptor--mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope (2000) 1.15

Chemotherapy-induced apoptosis. Adv Pharmacol (1997) 1.12

Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol (1996) 1.12

Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells. Mol Cancer Ther (2004) 1.11

Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene (2001) 1.08

Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res (2002) 1.06

New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. Cell Mol Life Sci (2004) 1.05

Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase. Oncogene (1995) 1.02

Epidermal growth factor receptor: association of extracellular domain negatively regulates intracellular kinase activation in the absence of ligand. Growth Factors (2003) 1.01

Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. Cancer Res (2006) 1.00

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene (1998) 0.98

Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. Am J Clin Pathol (1994) 0.96

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol (2003) 0.95

Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res (1996) 0.93

Age-related loss of EGF-receptor related protein (ERRP) in the aging colon is a potential risk factor for colon cancer. Mech Ageing Dev (2004) 0.93

Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. Br J Cancer (2001) 0.92

Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol (1995) 0.90

Epidermal growth factor receptor-related protein: a potential therapeutic agent for colorectal cancer. Gastroenterology (2003) 0.88

Cloning of a novel EGFR-related peptide: a putative negative regulator of EGFR. Am J Physiol Cell Physiol (2001) 0.88

The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. Cancer Res (2003) 0.87

Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta (2011) 2.62

The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer (2010) 2.20

Fecal collection, ambient preservation, and DNA extraction for PCR amplification of bacterial and human markers from human feces. J Microbiol Methods (2007) 1.77

Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res (2008) 1.59

Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer (2008) 1.50

Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther (2005) 1.44

MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFβR2) in colon cancer cells. Carcinogenesis (2011) 1.33

Identification and characterization of a cell cycle and apoptosis regulatory protein-1 as a novel mediator of apoptosis signaling by retinoid CD437. J Biol Chem (2003) 1.33

Age-related increase in colorectal cancer stem cells in macroscopically normal mucosa of patients with adenomas: a risk factor for colon cancer. Biochem Biophys Res Commun (2008) 1.31

Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One (2013) 1.24

Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol (2012) 1.23

Colon cancer stem cells: implications in carcinogenesis. Front Biosci (Landmark Ed) (2011) 1.23

Cigarette smoke, inflammation, and lung injury: a mechanistic perspective. J Toxicol Environ Health B Crit Rev (2009) 1.22

Cell cycle- and apoptosis-regulatory protein-1 is involved in apoptosis signaling by epidermal growth factor receptor. J Biol Chem (2006) 1.22

Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res (2010) 1.22

Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial. World J Gastroenterol (2008) 1.17

Schlafen 3, a novel gene, regulates colonic mucosal growth during aging. Am J Physiol Gastrointest Liver Physiol (2009) 1.17

Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett (2009) 1.13

Down-regulation of miR-21 Induces Differentiation of Chemoresistant Colon Cancer Cells and Enhances Susceptibility to Therapeutic Regimens. Transl Oncol (2013) 1.12

Microtubule-dependent association of AKAP350A and CCAR1 with RNA stress granules. Exp Cell Res (2008) 1.11

Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells. Mol Cancer Ther (2004) 1.11

Schlafen-3: a novel regulator of intestinal differentiation. Biochem Biophys Res Commun (2009) 1.08

Cell cycle and apoptosis regulatory protein-1: a novel regulator of apoptosis in the colonic mucosa during aging. Am J Physiol Gastrointest Liver Physiol (2007) 1.06

Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21. PLoS One (2013) 1.03

Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. Nutr Cancer (2009) 1.02

Schlafen 3 induction by cyclic strain regulates intestinal epithelial differentiation. Am J Physiol Gastrointest Liver Physiol (2010) 1.01

Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. Cancer Res (2006) 1.00

Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res (2010) 1.00

EGFR regulation of colon cancer stem-like cells during aging and in response to the colonic carcinogen dimethylhydrazine. Am J Physiol Gastrointest Liver Physiol (2012) 1.00

Antagonist analogue of 6-[3'-(1-adamantyl)-4'-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPN-induced apoptosis but not cell-cycle arrest. J Med Chem (2004) 1.00

Transactivator of transcription-tagged cell cycle and apoptosis regulatory protein-1 peptides suppress the growth of human breast cancer cells in vitro and in vivo. Mol Cancer Ther (2007) 1.00

Transforming growth factor-beta stimulates intestinal epithelial focal adhesion kinase synthesis via Smad- and p38-dependent mechanisms. Am J Pathol (2008) 1.00

Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. Blood (2002) 0.99

Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res (2006) 0.98

Antagonists of anaphase-promoting complex (APC)-2-cell cycle and apoptosis regulatory protein (CARP)-1 interaction are novel regulators of cell growth and apoptosis. J Biol Chem (2011) 0.98

Aging and inflammation: etiological culprits of cancer. Curr Aging Sci (2009) 0.97

Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int J Cancer (2011) 0.97

Colorectal cancer: chemopreventive role of curcumin and resveratrol. Nutr Cancer (2010) 0.96

Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells. Am J Physiol Gastrointest Liver Physiol (2011) 0.95

Regression of early and intermediate stages of colon cancer by targeting multiple members of the EGFR family with EGFR-related protein. Cancer Res (2007) 0.94

Exfoliated cells in stool: a source for reverse transcription-PCR-based analysis of biomarkers of gastrointestinal cancer. Cancer Epidemiol Biomarkers Prev (2008) 0.93

ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. Mol Cancer Ther (2010) 0.93

Age-related loss of EGF-receptor related protein (ERRP) in the aging colon is a potential risk factor for colon cancer. Mech Ageing Dev (2004) 0.93

Mechanisms of curcumin- and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells. Nutr Cancer (2006) 0.91

A novel mechanism of cell growth regulation by Cell Cycle and Apoptosis Regulatory Protein (CARP)-1. J Mol Signal (2010) 0.91

Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. Blood (2003) 0.90

Cancer Stem Cells in Colorectal Cancer: Genetic and Epigenetic Changes. J Stem Cell Res Ther (2012) 0.90

Folic acid-mediated inhibition of serum-induced activation of EGFR promoter in colon cancer cells. Am J Physiol Gastrointest Liver Physiol (2004) 0.89

Combination of aging and dimethylhydrazine treatment causes an increase in cancer-stem cell population of rat colonic crypts. Biochem Biophys Res Commun (2009) 0.88

Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol (2009) 0.88

Epidermal growth factor receptor-related protein: a potential therapeutic agent for colorectal cancer. Gastroenterology (2003) 0.88

Folic acid mediated attenuation of loss of heterozygosity of DCC tumor suppressor gene in the colonic mucosa of patients with colorectal adenomas. Cancer Detect Prev (2003) 0.88

Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo. PLoS One (2012) 0.86

Associations between markers of colorectal cancer stem cells and adenomas among ethnic groups. Dig Dis Sci (2012) 0.86

Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis. Mol Cell Biochem (2014) 0.84

Age-associated loss of heterozygosity of tumor suppressor genes in the gastric mucosa of humans. Am J Physiol Gastrointest Liver Physiol (2002) 0.84

Apoptosis signaling by the novel compound 3-Cl-AHPC involves increased EGFR proteolysis and accompanying decreased phosphatidylinositol 3-kinase and AKT kinase activities. Oncogene (2004) 0.84

Pressure stimulates breast cancer cell adhesion independently of cell cycle and apoptosis regulatory protein (CARP)-1 regulation of focal adhesion kinase. Am J Surg (2006) 0.84

Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis. Mol Cell Biochem (2011) 0.84

CARP-1 functional mimetics: a novel class of small molecule inhibitors of medulloblastoma cell growth. PLoS One (2013) 0.83

TGF-beta1 modulates focal adhesion kinase expression in rat intestinal epithelial IEC-6 cells via stimulatory and inhibitory Smad binding elements. Biochim Biophys Acta (2008) 0.83

Cancer stem cells biomarkers in gastric carcinogenesis. J Gastrointest Cancer (2013) 0.83

Cell growth inhibition by okadaic acid involves gut-enriched Kruppel-like factor mediated enhanced expression of c-Myc. Cancer Res (2007) 0.82

Folic acid reduces nuclear translocation of beta-catenin in rectal mucosal crypts of patients with colorectal adenomas. Cancer Lett (2004) 0.82

Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor. Cancer Chemother Pharmacol (2010) 0.81

EGFR(s) in aging and carcinogenesis of the gastrointestinal tract. Curr Protein Pept Sci (2010) 0.81

Identification and Testing of Novel CARP-1 Functional Mimetic Compounds as Inhibitors of Non-Small Cell Lung and Triple Negative Breast Cancers. J Biomed Nanotechnol (2015) 0.80

Cyclin B and E2F-1 expression in prostate carcinoma cells treated with the novel retinoid CD437 are regulated by the ubiquitin-mediated pathway. Cancer Res (2002) 0.80

Regulation of TGF-alpha-induced activation of AP-1 in the aging gastric mucosa. Am J Physiol Gastrointest Liver Physiol (2003) 0.80

Do nutraceutics play a role in the prevention and treatment of colorectal cancer? Cancer Metastasis Rev (2010) 0.79

Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells. Cancer Res (2005) 0.79

Curcumin synergizes the growth inhibitory properties of Indian toad (Bufo melanostictus Schneider) skin-derived factor (BM-ANF1) in HCT-116 colon cancer cells. Anticancer Res (2009) 0.79

EGF-receptor related protein causes cell cycle arrest and induces apoptosis of colon cancer cells in vitro and in vivo. Anticancer Res (2004) 0.78

Reduced expression of epidermal growth factor receptor-related protein in hepatocellular carcinoma: implications for cancer growth. Digestion (2004) 0.78

EGF receptor-related protein (ERRP) inhibits invasion of colon cancer cells and tubule formation by endothelial cells in vitro. Anticancer Res (2006) 0.78

Expression of intestinal ornithine decarboxylase during postnatal development in neonatal rats. Biochim Biophys Acta (2002) 0.77

Cell cycle and apoptosis regulatory protein (CARP)-1 is expressed in osteoblasts and regulated by PTH. Biochem Biophys Res Commun (2013) 0.77

Expression of epidermal growth factor-receptor related protein (ERRP) in human colorectal carcinogenesis. Cancer Lett (2004) 0.76

EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new? Curr Drug Targets (2010) 0.76

H. heilmannii infection and gastric carcinogenesis. Indian J Gastroenterol (2008) 0.76

Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options. Methods Mol Biol (2015) 0.76

Auraptene and its effects on the re-emergence of colon cancer stem cells. Phytother Res (2012) 0.75

Novel cis-trans interactions are involved in post-transcriptional regulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mRNA. J Mol Signal (2010) 0.75

Cancer stem cells in ulcerative colitis. Onkologie (2011) 0.75

Di-Block PLCL and Tri-Block PLCLG Matrix Polymeric Nanoparticles Enhanced the Anticancer Activity of Loaded 5-Fluorouracil. IEEE Trans Nanobioscience (2016) 0.75

Di-Block PLCL and Tri-Block PLCLG Matrix Polymeric Nanoparticles Enhanced the Anticancer Activity of Loaded 5-Fluorouracil. IEEE Trans Nanobioscience (2016) 0.75